高危直肠癌短程放疗后术前化疗与手术的依从性和耐受性:RAPIDO试验结果
RAPIDO试验是一项国际多中心随机III期研究,纳入920例高危直肠癌患者,比较短程放疗后化疗再手术与长程放化疗后手术的依从性、毒性和术后并发症。实验组术前化疗依从性达84%,术前≥3级毒性发生率为48%,高于标准组的25%,但手术方式和术后并发症无显著差异。
要点
- 实验组84%患者接受至少75%规定化疗,标准组术后化疗依从性仅58%。
- 实验组术前≥3级毒性发生率为48%,标准组术前为25%,术后化疗期间为35%。
- 两组手术方式和术后并发症无统计学显著差异。
核心结论
- 实验性短程放疗后术前化疗可获得84%的术前系统治疗高依从性。
- 术前治疗期间观察到相当程度的毒性,但未导致手术方式或术后并发症的差异。
研究设计与样本
- 研究者发起的国际多中心随机III期试验,2011年6月至2016年6月共入组920例高危直肠癌患者,901例可评估(实验组460例,标准组441例)。
- 实验组接受5×5 Gy短程放疗后化疗(6周期CAPOX或9周期FOLFOX4)再手术;标准组接受长程放疗(25-28×2-1.8 Gy)联用卡培他滨后手术,并根据当地政策选择术后化疗(8周期CAPOX或12周期FOLFOX4)。
- 主要终点为疾病相关治疗失败时间,本报告聚焦依从性、毒性和术后并发症。
主要发现
- 实验组所有患者均接受5×5 Gy放疗,84%的患者接受至少75%的规定化疗。
- 标准组放化疗依从性为93%,术后化疗依从性为58%。
- 实验组术前治疗期间≥3级毒性发生率为48%,标准组术前为25%,术后化疗期间为35%。
- 两组手术方式和术后并发症无统计学显著差异。
关键数值与推荐
- 实验组化疗方案为6周期CAPOX或9周期FOLFOX4;标准组术后化疗为8周期CAPOX或12周期FOLFOX4。
- 标准组长程放疗剂量为25-28次×2-1.8 Gy,联用卡培他滨。
临床怎么用
- 短程放疗后术前化疗策略可实现较高的术前系统治疗依从性,但需关注术前≥3级毒性。
- 该策略未增加手术方式改变或术后并发症风险。
局限性
- 需要更长的随访时间来评估主要终点及相关结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision is widely accepted as the standard of care for high-risk rectal cancer. Adjuvant chemotherapy is advised in several international guidelines, although the survival benefit remains unclear and compliance is poor. The current multidisciplinary approach has led to major improvements in local control, yet the occurrence of distant metastases has not decreased accordingly. The combination of short-course radiotherapy (SCRT) and chemotherapy in the waiting period before surgery might have several benefits, including higher compliance, downstaging and better effect of systemic therapy. METHODS: This is an investigator-initiated, international multicentre randomized phase III trial. High-risk rectal cancer patients were randomized to SCRT followed by chemotherapy (6 cycles CAPOX or alternatively 9 cycles FOLFOX4) and subsequent surgery, or long-course radiotherapy (25-28 × 2-1.8 Gy) with concomitant capecitabine followed by surgery and optional postoperative chemotherapy (8 cycles CAPOX or 12 cycles FOLFOX4) according to local institutions' policy. The primary endpoint is time to disease-related treatment failure. Here, we report the compliance, toxicity and postoperative complications in both study groups. FINDINGS: Between June 2011 and June 2016, 920 patients were enrolled. Of these, 901 were evaluable (460 in the experimental arm and 441 in the standard arm). All patients in the experimental arm received 5 × 5 Gy radiotherapy, and 84% of all patients received at least 75% of the prescribed chemotherapy. In the standard arm, the compliance for CRT was 93% and 58% for postoperative chemotherapy. Toxicity ≥grade 3 occurred in 48% of patients in the experimental arm, compared to 25% of patients in the standard arm during preoperative treatment and 35% of patients during postoperative chemotherapy. No statistically significant differences in surgical procedures or postoperative complications were observed. INTERPRETATION: High compliance (84%) of preoperative systemic treatment could be achieved with the experimental approach. Although considerable toxicity was observed during preoperative therapy, this did not lead to differences in surgical procedures or postoperative complications. Longer follow-up time is needed to assess the primary endpoint and related outcomes.
引用
- van der Valk MJM, Marijnen CAM, van Etten B, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. Radiother Oncol. 2020. PMID: 32240909. doi:10.1016/j.radonc.2020.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。